Digital Therapeutics (DTx)
The Alcimed Healthcare team works in the field of DTx (Digital Therapeutics), or digital therapies, which is of increasing importance in the healthcare sector, by supporting its clients, particularly industrial players, to gain a better understanding of DTx, their definition, their value contribution for the pharmaceutical and medical device industry, or even the business models of tomorrow including DTx in the value proposition.
They trust us
The challenges related to digital therapeutics (DTx)
As digital technologies play an increasingly significant role in healthcare, digital therapies (DTx) are emerging to shake up our traditional approach to care. As with any emerging approach, there are many challenges related to digital therapies:
DTx, digital therapeutics, digital therapies, … The definition of a DTx in the technical or regulatory sense may vary according to the stakeholders concerned or the countries investigated. Our clients wonder what a DTx is, what characterizes it, the expected level of proof, or even the regulatory dimensions necessary for their approval. Sometimes an awareness-raising exercise is necessary :
How do we convince internally of the need to integrate DTx into medium-term strategic thinking?
How do we create value from a DTx and what are the market access patterns: insurers, employers, partnerships with the pharmaceutical company, etc.?
Beyond the construction of business models, Alcimed can also support its customers when searching for or evaluating potential partners before devising a collaboration, for example.
Who “sells” DTx? How do we ensure their prescription and the commitment of health professionals alongside patients, etc.?
Such questions can be tackled by benchmarks or, once again, a search for partners. From a perspective where the DTx are integrated into the care pathways, understanding how to fit them in and promoting their place represents an important strategic issue for stakeholders in the world of healthcare.
From a perspective where the DTx are integrated into the care pathways, understanding how to fit them in and promoting their place represents an important strategic issue for stakeholders in the world of healthcare and digital health.
How we support you in your projects related to digital therapeutics (DTx)
We work both on technological or entrepreneurial state of the art and on market considerations such as the creation of business models or the search for partners. These questions are addressed to us both by pharmaceutical or medtech industrial players and by pure DTx players.
To answer these questions, Alcimed combines external investigation (monitoring and benchmarking, interactions with stakeholders in the sector, etc.) and often internal analysis to align key functions for our clients in the field of DTx. The innovation, R&D, marketing/sales departments, etc. can be involved in the reflection to facilitate a 360° vision of the subject.
Alcimed acts as a partner for its clients on these topics, highlighting our recognized expertise in healthcare, new technologies, and digital technology.
Examples of recent projects carried out for our clients in digital therapeutics
Development of the DTx strategic roadmap for a pharmaceutical laboratory
Alcimed supported a European pharmaceutical laboratory in its DTx thinking, the objective of which was to formalize a roadmap for future investments in the field.
Through monitoring and internal discussions, we built an organizational and governance proposal for the laboratory by addressing key questions: how does the DTx strategy fit in with the laboratory’s portfolio? What functions should a “DTx hub” include? Which therapeutic areas are most directly affected by the topic? This roadmap was ultimately presented to the laboratory’s general management.
In-depth analysis of partners in DTx and digital health for a pharmaceutical laboratory
As part of its support for a European pharmaceutical laboratory, Alcimed regularly carries out expert appraisals and in-depth analyses of innovative start-ups and SMEs with a view to partnerships or co-development.
Several of these “targets” have a DTx positioning, and, in these analyses, Alcimed interacts directly with the companies of interest to understand their degree of maturity, their DTx value proposition, their inclinations to work with the pharmaceutical company, and their practical needs.
The desired goal, when a partnership is created, is to catalyze the emergence of the DTx industry by accelerating the marketing of digital therapies!
Strategic evaluation of a digital health opportunity in the pain management market
We supported a pharmaceutical company to take a position on a proposed buyout for a new digital pain management solution.
We characterized the key markets in pain management by segmenting them by geography and use cases, and we assessed the potential for the solution, taking into account regulatory specificities, market access specificities, cultural habits, etc.
Finally, we validated the start-up’s value proposition and recommended to our client to proceed with the technical due diligence.
Critical analysis of clinical evidence provided by companies offering coaching applications for patients with diabetes
We supported a European pharmaceutical company to carry out a state-of-the-art research in the field of DTX to induce behavioral change.
The objective was to define the clinical evaluation criteria that can be used to demonstrate the effectiveness of these approaches for patients with chronic diseases, in this case diabetes. We then carried out a search for active partners in the field, and we assessed the level of evidence provided by referring to the state of the art produced as well as the proposed business models.
Finally, we organized an ad-board to challenge our analysis and finalize the selection of the most relevant partners for our client.
You have a project?
To go further
3 myths about Digital Therapeutics (DTx) and the implications for pharma companies
The forecasted Digital therapeutics (DTx) global market annual growth for the upcoming years gravitates around 20%. This fast development triggers questions concerning the place of DTx in the ...
Digital Therapeutics: A development axis of the pharmaceutical industry
A definition of digital therapeutics Digital therapies (or DTx for "digital therapeutics") form a new therapeutic approach. They are digital solutions that have demonstrated a direct impact on the ...
3 tips for building the future care pathway
Emergency room crisis, doctor shortage, ecology... The future care pathways must respond to a variety of challenges. Here are 3 tips to help you build them.
Founded in 1993, Alcimed is an innovation and new business consulting firm, specializing in innovation driven sectors: life sciences (healthcare, biotech, agrifood), energy, environment, mobility, chemicals, materials, cosmetics, aeronautics, space and defence.
Our purpose? Helping both private and public decision-makers explore and develop their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate.
Located across eight offices around the world (France, Europe, Singapore and the United States), our team is made up of 220 highly-qualified, multicultural and passionate explorers, with a blended science/technology and business culture.
Our dream? To build a team of 1,000 explorers, to design tomorrow’s world hand in hand with our clients.
DTx are digital medical devices for prevention, treatment, or follow-up purposes in patient care, actively participating in a mechanism of action and based on clinical evidence. It is still a young concept (<10 years) which aims to become a new section of medicine alongside traditional approaches based on chemistry and biology.